---
figid: PMC6046102__12943_2018_850_Fig1_HTML
figtitle: 'TNBC: The current and upcoming therapeutic strategies targeting the mutant
  proteins or pathways to enable tailored-therapeutics'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6046102
filename: 12943_2018_850_Fig1_HTML.jpg
figlink: /pmc/articles/PMC6046102/figure/Fig1/
number: F1
caption: 'TNBC: The current and upcoming therapeutic strategies targeting the mutant
  proteins or pathways to enable tailored-therapeutics. Therapeutics target at genetic
  alterations include defects in DNA damage repair, TP53 mutations, activation of
  PI3K pathway, EGFR amplification/mutations, activation of RAF-MEK signaling, and
  Rb loss. These genetic alterations were summarized in the white boxes of the diagram.
  Potential therapeutic strategies were depicted in red boxes'
papertitle: Therapeutic landscape in mutational triple negative breast cancer.
reftext: Yaqin Shi, et al. Mol Cancer. 2018;17:99.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9661616
figid_alias: PMC6046102__F1
figtype: Figure
redirect_from: /figures/PMC6046102__F1
ndex: 28e4dd5d-ded1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6046102__12943_2018_850_Fig1_HTML.html
  '@type': Dataset
  description: 'TNBC: The current and upcoming therapeutic strategies targeting the
    mutant proteins or pathways to enable tailored-therapeutics. Therapeutics target
    at genetic alterations include defects in DNA damage repair, TP53 mutations, activation
    of PI3K pathway, EGFR amplification/mutations, activation of RAF-MEK signaling,
    and Rb loss. These genetic alterations were summarized in the white boxes of the
    diagram. Potential therapeutic strategies were depicted in red boxes'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - INPP5D
  - PTEN
  - INPP4B
  - SERPINA4
  - PI3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - KRAS
  - NRAS
  - NF1
  - DUSP4
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - TP53
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - TP63
  - TP73
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - CHEK2
  - CHEK1
  - BRCA1
  - CDC25A
  - MIR155HG
  - BRCA2
  - WARS1
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - ATM
  - CDC25B
  - CDC25C
  - Tyrosine
  - BIC
  - Breast cancer
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Melanoma
---
